ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture
Legend Biotech presented preliminary results from its ongoing Phase I/II trial of LB2102 (NCT05680922), an armoured delta-like ligand…
Browsing Tag